Form 4: Apyx Medical Corp Director Lawrence Waldman Acquires 17,000 Stock Options

Director Lawrence Waldman acquired 17,000 stock options in Apyx Medical Corp on August 8, 2024, as part of the Director Compensation Program.

Summary

• Lawrence Waldman, a director of Apyx Medical Corp, acquired 17,000 stock options on August 8, 2024.
• The options have an exercise price of $1.02.
• These options were issued as part of the Issuer's Director Compensation Program.
• The options vest ratably over a 12-month period and become fully vested and exercisable on the first anniversary of the date of grant.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The document simply reports a standard stock option grant to a director, which is a common practice. It suggests alignment of interests between the director and shareholders.

Positives

• The grant of stock options to directors aligns their interests with those of the shareholders.

Industry Context

Stock option grants to directors are a common practice in corporate governance to incentivize and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary significantly across industries and company sizes.
• Benchmarking against peer companies in the medical device sector would provide a more detailed assessment of the appropriateness of this grant.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance improves the company's financial results.

Key Dates